Jump to ContentJump to Main Navigation
Reimagining Global Abortion PoliticsA Social Justice Perspective$
Users without a subscription are not able to see the full content.

Fiona Bloomer, Claire Pierson, and Sylvia Estrada Claudio

Print publication date: 2018

Print ISBN-13: 9781447340430

Published to Policy Press Scholarship Online: September 2019

DOI: 10.1332/policypress/9781447340430.001.0001

Show Summary Details
Page of

PRINTED FROM POLICY PRESS SCHOLARSHIP ONLINE (www.policypress.universitypressscholarship.com). (c) Copyright Policy Press, 2021. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in PPSO for personal use.date: 26 September 2021

The biomedicalisation of abortion

The biomedicalisation of abortion

Chapter:
(p.31) Three The biomedicalisation of abortion
Source:
Reimagining Global Abortion Politics
Author(s):

Fiona Bloomer

Claire Pierson

Sylvia Estrada Claudio

Publisher:
Policy Press
DOI:10.1332/policypress/9781447340430.003.0003

This chapter discusses the development of the bio-medicalisation of abortion. Recent history reveals the key role played by pharmaceutical companies in the development of a medication to induce abortion (Mifepristone) and how localised knowledge amongst women identified the abortifacient properties of a second medication (Misoprostol). Whilst the bio-medicalisation of abortion was initially hailed as a way to put women at the centre of the process, its implementation was not without problems. The impact of commercial pressures on pharmaceutical companies is discussed, as well as challenges faced by those accessing the medication without adequate information on dosage and usage. The case study of Brazil highlights the hugely significant role played by women in communities experiencing multiple barriers to accessing abortion, sharing knowledge about medication which having been developed for other purposes, became known for its abortifacient purposes. The impact of the Zika virus in 2015 highlights how severe inadequacies within reproductive health policy affected women and their families. The chapter concludes by considering the impact of the bio-medicalisation on health professionals and the changing dynamic in the relationship between clinician and the woman seeking an abortion.

Keywords:   biomedicalisation, pharmaceutical companies, abortifacients, Mifepristone, Misoprostol, Zika, Brazil, abortion providers

Policy Press Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us.